NCT03880721
Unknown
Not Applicable
By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation
Chinese PLA General Hospital1 site in 1 country200 target enrollmentJanuary 1, 2019
ConditionsHepatocellular Carcinoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatocellular Carcinoma
- Sponsor
- Chinese PLA General Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Specificity
- Last Updated
- 6 years ago
Overview
Brief Summary
Developing a radiomics model to predict the prognosis of patients with hepatocellular carcinoma after microwave ablation to provide advice for their treatment.
Investigators
Ping Liang
Prof.
Chinese PLA General Hospital
Eligibility Criteria
Inclusion Criteria
- •Patients with primary hepatocellular carcinoma in the department of interventional ultrasound, PLA general hospital, who accept MWA therapy for HCC
- •Inclusion criteria:
- •Primary hepatocellular
- •No other treatments ware performed before microwave ablation
- •Patient has been clinically diagnosed with HCC definitely, and have a definite operational indication
- •No extrahepatic manifestations and no evidence of vessel invasion and bile duct thrombi
Exclusion Criteria
- •Exclusion criteria:
- •Non-primary hepatocellular carcinoma or hepatic metastases
- •Accept other treatment before microwave ablation
- •Extrahepatic metastasis, vessel invasion or bile duct thrombi
Outcomes
Primary Outcomes
Specificity
Time Frame: through study completion, an average of 2 year
diagnosis specificity of intelligent ultrasound analysis
AUC value
Time Frame: through study completion, an average of 2 year
Utilizing area under curve to judge the accurency
Sensitivity
Time Frame: through study completion, an average of 2 year
diagnosis sensitivity of intelligent ultrasound analysis
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Radiomics of Hepatocellular CarcinomaHepatocellular CarcinomaNCT02757846Chinese Academy of Sciences1,200
Active, not recruiting
Not Applicable
Artificial Intelligence and Hepatocellular CarcinomaHCCNCT05637788Humanitas Clinical and Research Center535
Completed
Not Applicable
The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder CancerBladder CancerRadiomicsImmunotherapyNCT06381895Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1,200
Recruiting
Not Applicable
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabAdvanced Hepatocellular CarcinomaNCT05173298CHA University100
Unknown
Not Applicable
Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver MetastasesColon CancerRectal CancerLiver MetastasesNCT04213222Peking University People's Hospital300